Personalized blood thinners could cut stroke risk

NCT ID NCT06269432

Completed Disease control Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a blood test to guide antiplatelet medication can reduce the risk of a second stroke. People who have had a non-cardioembolic ischemic stroke and are already taking aspirin will be assigned to either continue standard aspirin or switch to a different antiplatelet drug based on their test results. The goal is to see if personalized treatment lowers the rate of blood clot-related events within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aspirin, clopidogrel, ticagrelor
What this could lead to: If successful, this approach could help doctors choose the right antiplatelet drug for each stroke patient, potentially lowering the chance of another stroke or heart attack.
What could go wrong: This is a single trial with 1,224 participants, and results may not apply to all stroke patients. There is also a risk of bleeding with antiplatelet drugs, which the study will monitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPLATELET DRUG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIPLATELET DRUG ISCHEMIC STROKE

Contacts and locations

Locations

Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.